



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

March 18, 2014

Via Email  
Leo Ehrlich  
Chief Executive and Financial Officer  
Cellceutix Corporation  
100 Cummings Center, Suite 151-B  
Beverly, MA 01915

**Re: Cellceutix Corporation**  
**Form 10-K for the year ended June 30, 2013**  
**Filed September 30, 2013**  
**File No. 000-52321**

Dear Mr. Ehrlich:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

*/s/ Bryan J. Pitko* for

Jeffrey P. Riedler  
Assistant Director